TR200003333T2 - Benzothiophins useful in the treatment of insulin resistance and hyperglycemia - Google Patents

Benzothiophins useful in the treatment of insulin resistance and hyperglycemia

Info

Publication number
TR200003333T2
TR200003333T2 TR2000/03333T TR200003333T TR200003333T2 TR 200003333 T2 TR200003333 T2 TR 200003333T2 TR 2000/03333 T TR2000/03333 T TR 2000/03333T TR 200003333 T TR200003333 T TR 200003333T TR 200003333 T2 TR200003333 T2 TR 200003333T2
Authority
TR
Turkey
Prior art keywords
hyperglycemia
useful
treatment
insulin resistance
benzothiophins
Prior art date
Application number
TR2000/03333T
Other languages
Turkish (tr)
Inventor
Edward Wrobel Jay
Joan Dietrich Arlene
Miyoko Antane Madelene
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Publication of TR200003333T2 publication Critical patent/TR200003333T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Abstract

Bu bulus,ensülin direngenligine veya hiperglisemiye bagli metabolik bozukluklarin tedavisinde yararli olan formül (I)'e iliskin bilesikleri saglamakta olup Ar burada (a), (b) veya (c)'dir. A,B,C,D,E,X,Y,Z1 ve Z2 burada tanim bölümünde tarif edildigi gibidir veya bunlarin farmakolojik olarak kabul edilebilir tuzlaridir.This invention provides compounds of formula (I) useful for the treatment of metabolic disorders due to insulin resistance or hyperglycemia, where Ar is (a), (b) or (c). A, B, C, D, E, X, Y, Z1 and Z2 are as described herein or their pharmacologically acceptable salts.

TR2000/03333T 1998-05-12 1999-05-10 Benzothiophins useful in the treatment of insulin resistance and hyperglycemia TR200003333T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7671298A 1998-05-12 1998-05-12

Publications (1)

Publication Number Publication Date
TR200003333T2 true TR200003333T2 (en) 2001-02-21

Family

ID=22133746

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03333T TR200003333T2 (en) 1998-05-12 1999-05-10 Benzothiophins useful in the treatment of insulin resistance and hyperglycemia

Country Status (22)

Country Link
EP (1) EP1077969A1 (en)
JP (1) JP2002516321A (en)
KR (1) KR20010043539A (en)
CN (1) CN1308626A (en)
AR (1) AR015294A1 (en)
AU (1) AU756337B2 (en)
BG (1) BG104918A (en)
BR (1) BR9911779A (en)
CA (1) CA2330620A1 (en)
EA (1) EA200001175A1 (en)
EE (1) EE200000653A (en)
HR (1) HRP20000767A2 (en)
HU (1) HUP0101792A3 (en)
ID (1) ID26244A (en)
IL (1) IL139132A0 (en)
NO (1) NO20005677L (en)
PL (1) PL344081A1 (en)
SK (1) SK16992000A3 (en)
TR (1) TR200003333T2 (en)
TW (1) TW510900B (en)
WO (1) WO1999061435A1 (en)
ZA (1) ZA200005961B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
WO2002018363A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
WO2002026707A1 (en) * 2000-09-26 2002-04-04 Biovitrum Ab Novel compounds
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
US20020198201A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an aldose reductase inhibitor
US20030013709A1 (en) * 2001-06-07 2003-01-16 Wyeth Combination of a PTPase inhibitor and an alpha-glucosidase inhibitor
WO2002098409A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination therapy for type ii diabetes or syndrome x
WO2002100398A1 (en) * 2001-06-07 2002-12-19 Wyeth Combination of a ptpase inhibitor and an ace inhibitor
WO2002098408A1 (en) * 2001-06-07 2002-12-12 Wyeth Ptpase inhibitors for improving cardiovascular risk profile
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
WO2002098414A1 (en) * 2001-06-07 2002-12-12 Wyeth Methods using ptpase inhibitors and insulin
WO2002098410A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination of a ptpase inhibitor and a sulfonylurea agent
WO2002100397A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
ATE367812T1 (en) 2001-06-20 2007-08-15 Wyeth Corp SUBSTITUTED INDOLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
JP2005508355A (en) 2001-10-19 2005-03-31 トランス　テック　ファーマ，インコーポレイテッド Bis-heteroarylalkanes as therapeutic agents
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
ITMI20022172A1 (en) * 2002-10-14 2004-04-15 Clariant Lsm Italia Spa PROCESS FOR THE PREPARATION OF 3-ALCHYL-THIOPHENI-2, 5-REPLACED.
DE60324183D1 (en) 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
BR0316574A (en) 2002-12-10 2005-10-04 Wyeth Corp Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as plasminogen activator inhibitor-1 inhibitors (parent-1)
EP1569899B1 (en) 2002-12-10 2006-06-28 Wyeth Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7718377B2 (en) 2003-05-29 2010-05-18 Kyoto Pharmaceutical Industries, Ltd. Insulin resistance curative and method of screening the same
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
FR2862645B1 (en) * 2003-11-20 2007-06-22 Merck Sante Sas ANTIDIABETIC COMPOUNDS CONTAINING BENZOFURAN, BENZOTHIOPHENIC DERIVATIVES
CN101039936A (en) 2004-08-23 2007-09-19 惠氏公司 Oxazolo-naphthyl acids as plasminogen activator inhibitor type-1(pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
EP1919866A2 (en) 2005-08-17 2008-05-14 Wyeth a Corporation of the State of Delaware Substituted indoles and use thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
GB0822486D0 (en) 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN105592846A (en) 2013-03-15 2016-05-18 持田制药株式会社 Compositions and methods for treating non-alcoholic steatohepatitis
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
CN106749169B (en) * 2016-11-07 2020-04-21 浙江工业大学 Chiral preparation method of Ertiprotafib
CN107033122B (en) * 2017-05-19 2019-06-14 南方医科大学 A kind of N- aryl -2- thiophene-carboxamides analog derivative and its preparation method and application
WO2019208713A1 (en) 2018-04-26 2019-10-31 国立大学法人東京工業大学 Method for promoting differentiation of pluripotent stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505846A (en) * 1968-08-15 1971-04-15 Parke Davis & Co Process for the preparation of new heterocyclic compounds
US3639422A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 4-phenylindole-1 (and 7)-acetic acids
US3682976A (en) * 1970-02-16 1972-08-08 Parke Davis & Co Phenyl benzofuran acetic acid compounds
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
FR2599740B1 (en) * 1986-06-05 1988-08-12 Rhone Poulenc Sante BENZO (B) THIOPHENE DERIVATIVES OF BENZO (B) FURANNECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM
JPH01135766A (en) * 1987-11-20 1989-05-29 Tanabe Seiyaku Co Ltd Biphenyl derivative
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
DE4425613A1 (en) * 1994-07-20 1996-01-25 Bayer Ag 5-membered heteroaryl oxazolidinones

Also Published As

Publication number Publication date
AR015294A1 (en) 2001-04-18
WO1999061435A1 (en) 1999-12-02
JP2002516321A (en) 2002-06-04
TW510900B (en) 2002-11-21
EE200000653A (en) 2002-04-15
AU3893999A (en) 1999-12-13
KR20010043539A (en) 2001-05-25
EP1077969A1 (en) 2001-02-28
CN1308626A (en) 2001-08-15
SK16992000A3 (en) 2001-04-09
ZA200005961B (en) 2001-10-24
HRP20000767A2 (en) 2001-10-31
PL344081A1 (en) 2001-09-24
NO20005677D0 (en) 2000-11-10
ID26244A (en) 2000-12-07
HUP0101792A2 (en) 2002-01-28
BR9911779A (en) 2001-02-06
NO20005677L (en) 2000-12-05
CA2330620A1 (en) 1999-12-02
BG104918A (en) 2001-08-31
EA200001175A1 (en) 2001-06-25
HUP0101792A3 (en) 2003-01-28
IL139132A0 (en) 2001-11-25
AU756337B2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
TR200003333T2 (en) Benzothiophins useful in the treatment of insulin resistance and hyperglycemia
SE9604786D0 (en) New compounds
SE9504661D0 (en) New compounds
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
DK0977741T3 (en) Substituted phenyl derivatives, their preparation and use
SE0001899D0 (en) New compounds
ATE306261T1 (en) ANTITHROMBOTIC AGENTS
TR200001973T2 (en) Methods for the manufacture and pharmaceutical production of pharmaceutical compositions containing 11 ß-halogen-7alpha-substituted-estratrienes, these 11ß-halogen-7alpha-substituted-estratrienes.
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
DE60236541D1 (en) INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE TYPE 1
MY146279A (en) Compounds affecting glucokinase
NO20040096L (en) Taxol-improvement relations
BR0109703A (en) Piperazine Derivatives
ES2184077T3 (en) NEW FENANTRIDINS REPLACED IN POSITION 6.
DE60045508D1 (en) DALDA ANALOGS AND THEIR USE
DE69928226D1 (en) CHEMOKIN RECEPTOR ANTAGONISTS AND CONSUMPTION
ATE303384T1 (en) 1-BIARYL-1,8-NAPHTHYRIDINE-4-ONE AS PHOSPHODIESETERASE INHIBITORS
SE9802208D0 (en) Novel compounds
SE9802206D0 (en) Novel compounds
ATE174508T1 (en) USE OF BIS (AMIDINOBENZIDAZOLE) FOR PRODUCING A MEDICATION FOR INHIBITING RETROVIRAL INTEGRASE
IT1318667B1 (en) ANTI-INFLAMMATORY DRUG.
DK0750616T3 (en) Acid addition salts of 2,3,4,5-tetrahydro-1H-3-benzazapine compounds
SE9802209D0 (en) Novel compounds
SE9504662D0 (en) New compounds
DE60121048D1 (en) PYRAZINOi1'2 ': 1,6öPYRIDOi3,4-BöINDOLDERIVATE